🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As we embark on the next exciting phase of advancing our pipeline of programs, we are excited to welcome Robert Hofmeister Ph.D., as our Chief Scientific Officer. His expertise and stellar track record, will drive innovation and scientific excellence tinyurl.com/y695pn62

On #WorldCancerDay, we honor the millions of fighters, celebrate survivors, and remember the brave souls we've lost. annie, we remain committed to leveraging science and tech to help save lives. #CancerAwareness #InnovationAgainstCancer

On #RareDiseaseDay, Myeloid Therapeutics stands with the rare disease community, celebrating resilience and driving innovation. This year, hope abounds for the impact of our CREATE platform – a leap forward, making gene editing possible & accessible; Learn more: tinyurl.com/yx4hshpc

Mark your calendars for Myeloid's updates on our RNA Immunotherapies at the #AACR24 next month. Join us to learn about our cutting-edge approach and its potential impact on cancer immunotherapy tinyurl.com/4f43ezzh

On #internationalwomensday2024 join us in celebrating the incredible women Myeloid Therapeutics who are driving innovation and the countless women around the world who inspire us all! We are proud to have such an extraordinary group of women on our team. #inspireinclusion #womeninscience

Join us at AACR Mon, April 8th when we share data supporting MT-302, the world’s first clinical stage in vivo mRNA CAR drug development candidate and we showcase our diverse mRNA platform. More info: lnkd.in/eqGyCrhx #AACR24

This week, Myeloid Therapeutics is in Baltimore for #ASGCT2024. We are presenting multiple posters showcasing the clinical progress of MT-302, the world’s first in vivo mRNA CAR drug candidate, and our CREATE platform technology for precision RNA-mediated gene editing and delivery.

Our in vivo mRNA CAR, MT-302, continues progressing well in the ongoing clinical studies, with plans for expanded clinical use. Daniel Getts, PhD, our CEO, shared we're expanding plans for MT-302’s clinical use, given several inherent product advantages for patients. #ASGCT2024

This week at #APVIC 2024, our CSO, Robert Hofmeister, Ph.D., showcased Myeloid's cutting-edge in vivo mRNA engineering technology and in vivo clinical pipeline.  More details can be found here: apvic.org #APVIC24 #mRNA #invivo #biotech

Next week, we're headed to the #JefferiesHealthcare Conference Private Biotech Day! The Myeloid Therapeutics management team will be meeting with investors 1:1 to discuss our industry-leading in vivo mRNA engineering technology & expanding clinical pipeline. bit.ly/3X3bOFT

Jerome Chal, Myeloid's SVP and Head of CMC, presents today in Boston at the 2024 Cell & Gene Therapy Summit. He will describe Myeloid's acceleration of in vivo programming of immune cells for patients combating solid tumors.  More detail here: bit.ly/3WeHMOE #CGT2024

#BreakingNews  We announced today that we are dosing patients with our second in vivo mRNA CAR, MT-303, a novel GPC3 targeting RNA CAR, in a Phase 1 study for the treatment of advanced hepatocellular carcinoma, the most prevalent form of liver cancer.   bit.ly/46qQ3Ta

At Myeloid, our mission is to develop RNA therapeutics to conquer cancer - dosing our first patient with MT-303 in our Phase 1 study brings us one step closer to achieving our goal. Learn more about our clinical trials here:  myeloidtx.com/patients/ #oncology

W are looking forward to participating in the Barclays Bank Biotech: 1x1 Private Company Symposium on August 7, 2024. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology. prnewswire.com/news-releases/…

We are excited to continue to tell the Myeloid Therapeutics story at several upcoming conferences in September and October. More details can be found here: prnewswire.com/news-releases/… #biotech #mRNA

Thank you, #ESMO2024 organizers, for showcasing Myeloid's Trials-in-Progress poster on the MYE Symphony Study (NCT05969041), a First-in-Human Phase 1 trial evaluating our innovative MT-302 program. MT-302 is our lead in vivo #mRNA CAR targeting TROP2+ epithelial malignancies.

At 9:30 am today, Myeloid Therapeutics's CEO, Daniel Getts, PhD, is speaking at #BioEurope in the Immuno-Oncology session. We look forward to showcasing our science and mRNA-based clinical pipeline. Learn more here: informaconnect.com/bioeurope/ #Biotech #mRNA

Myeloid Therapeutics will participate in the #JefferiesHealthcare Conference beginning Nov. 19. Members of the management team will meet with investors one-on-one and conduct B-to-B meetings to discuss our industry-leading in vivo mRNA engineering technology. prnewswire.com/news-releases/…

Next week at #JPM2025, our CEO Daniel Getts, Ph.D., will present on Wednesday, January 15, 2025, at 8:30 am PT. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo #mRNA engineering technology. prnewswire.com/news-releases/…

timmermanreport.com/2025/01/austra…